Coenzyme drugs are nucleotide derivatives that participate in the synthesis and metabolism of phospholipids and nucleic acids in the body. They are intermediate products and energy sources for brain phospholipid synthesis and nucleic acid metabolism.

This product is an anti-tuberculosis drug. Isoniazid has a highly selective antibacterial effect on all types of Mycobacterium tuberculosis. It is the synthetic antibacterial drug with the strongest bactericidal effect among current anti-tuberculosis drugs, and has almost no effect on other bacteria. It has a strong effect on Mycobacterium tuberculosis in the growth and reproduction stage, but a weaker and slower effect on the dormant stage. Its mechanism of action may be to inhibit the synthesis of mycolic acid in sensitive bacteria and cause the cell wall to rupture.

It has highly selective antibacterial effects on all types of Mycobacterium tuberculosis. It is the synthetic antibacterial drug with the strongest bactericidal effect among current anti-tuberculosis drugs, and has almost no effect on other bacteria. It has a strong effect on Mycobacterium tuberculosis in the growth and reproduction stage, but a weaker and slower effect on the dormant stage. Its mechanism of action may be to inhibit the synthesis of mycolic acid in sensitive bacteria and cause the cell wall to rupture.

It stimulates the adrenergic receptors of the sympathetic nervous system and the dopamine receptors located in the kidney, mesentery, coronary artery, and cerebral artery, and its effect is dose-dependent. At low doses (0.5-2μg/kg per minute based on body weight), it mainly acts on dopamine receptors, dilates the blood vessels of the kidney and mesentery, increases renal blood flow and glomerular filtration rate, and increases urine volume and sodium excretion; at small to medium doses (2-10μg/kg per minute based on body weight), it can directly stimulate β1 receptors and indirectly promote the release of norepinephrine from storage sites, produce positive stress on the myocardium, increase myocardial contractility and stroke volume, and ultimately increase cardiac output, systolic blood pressure, and possibly increase pulse pressure, with no change or slight increase in diastolic blood pressure, and peripheral total resistance often unchanged, and coronary blood flow and oxygen consumption improved; at high doses (more than 10μg/kg per minute based on body weight), it stimulates α receptors, resulting in increased peripheral vascular resistance, renal vasoconstriction, and reduced renal blood flow and urine volume. Due to the increase in cardiac output and peripheral vascular resistance, both systolic and diastolic blood pressures increase. (1) It stimulates the cardiac β1 receptors and has a much stronger effect on increasing myocardial contractility; (2) It increases the blood flow to the kidneys and mesentery, which can prevent the malignant development of shock caused by ischemia of these organs. Under the same condition of increasing myocardial contractility, the effects of causing arrhythmias and increasing myocardial oxygen consumption are weaker. In short, dopamine is particularly suitable for shock patients with weakened myocardial contractility, decreased urine output, and replenished blood volume.